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ABSTRACT: Anthrax is a zoonotic disease caused by Bacillus anthracis, a Gram-positive, non-motile, 
spore-forming bacterium. It is a globally distributed disease, having been reported from all continents that are 
populated heavily with animals and humans. The objectives were to review general laboratory diagnostic 
testing methods and reported outbreaks of anthrax in Ethiopia. Anthrax was second top zoonotic priority next 
to rabies and endemic in Ethiopia that may occur in May and June every year (Anthrax season) in several 
farming localities. Animal hosts acquire the disease through grazing, usually by ingestion or inhalation while 
there are three major routs of transmission: ingestion, inhalation and cutaneous. This review indicated that 
anthrax remains to be major public and animal health problem in Ethiopia. Although suspected cases of 
anthrax are reported from several districts, they are not well confirmed by laboratories. Prevention and control 
of anthrax in animals effectively reduces its impact on public health and the national economy. The control of 
anthrax outbreaks among domestic animals is primarily dependent on rapid identification and treatment of 
affected animals; enhanced surveillance for additional cases; implementation of control measures including 
quarantine, prophylaxis, vaccination and the proper disposal of dead animals with decontamination is critical. 
Keywords: Anthrax; Bacillus anthracis; Diagnosis; Toxins; Zoonosis. 
1. INTRODUCTION 
 Anthrax is naturally occurring diseases of warm-blooded animals, including humans. The disease is 
caused by B. anthracis, a gram-positive, non-motile, endospore-forming bacterium [1, 2]. The name of the 
bacterium is derived from “anthrakis”, the Greek word for coal, because anthrax in humans causes black, 
coal-like lesions on the skin at the site of inoculation [3]. World Health Organization Collaborating Center for 
Remote Sensing and Geographic Information Systems for Public Health (WHOCC) recorded anthrax 
outbreaks in animals are in nearly 200 countries by The World Anthrax Data Site. Country-of-origin, anthrax 
status, vaccination program, species affected, year of outbreak, number of outbreaks during the year, number 
of cases, number vaccinated and total livestock population were types of data recorded by The World Anthrax 
Data Site [4]. 
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Anthrax is worldwide distributed disease, having been reported from all continents that are populated 
heavily with animals and humans. WHOCC [4] classified the status of anthrax as hyperendemic/epidemic, 
endemic, sporadic, probably free, free and unknown.  The countries with hyperendemic/epidemic status are 
more frequent in Africa, although the status of Egypt is “Probably free”. Examples of regions with unknown 
anthrax status are the polar extremes, the Arctic and the Antarctic [5].  
Anthrax is currently recognized as a neglected zoonosis, causing a public health threat in many regions 
of the world, particularly in Africa [6]. The bacterium forms spores when exposed to oxygen and allowing it 
to remain viable in the environment for many years before coming into contact with a susceptible host and 
when exposed to a nutrient rich environment, such as the tissues or blood of an animal or human host [7, 8]. 
Molecular monomorphic characteristics of B. anthracis is challenging for differentiation by PCR. 
However, VrrA, gene containing variable-numbers of tandem repeats region (VNTR) involving five variants 
differing in the number of copies. Rapid PCR analysis can be used to distinguish the five variants and based 
on the number of VNTRs, it is possible to classify various strain and various withe the geographical origin of 
the isolates [9].  
Moreover, the tripartite ministries, Ministry of Livestock and Fisheries (Currently Ministry of 
Agriculture), Ministry of Health and Ministry of Culture and Tourism (through the Ethiopian Wildlife 
Protection Authority), in collaboration with development partners established a national One Health Platform 
(OHP) with various technical working groups. Since the national OHP was established, various activities have 
been undertaken. One of the tasks was developing a list of priority zoonotic diseases as an entry for a multi-
sectoral joint action to reduce and combat the impact of zoonotic diseases on public and animal health as well 
as on the national economy. The national zoonotic disease prioritization was conducted using a tool developed 
by CDC and resulted in 5 priority zoonotic diseases for inter sectoral collaboration of which anthrax was the 
second top priority next to rabies [10].  
Animal anthrax is an endemic disease and seasonal in Ethiopia which occurs in May and June every 
year in different localities of the country. Several districts of the country are reporting suspected cases of 
anthrax outbreaks in animals, few of those are confirmed by laboratory [11] and research was not done yet to 
understand epidemiology of anthrax disease outbreak. To date, anthrax outbreak reports are based on history 
and clinical signs in both public and animal health sector. In addition to limitations in confirming anthrax, 
biosafety and biosecurity issues are also of major concern for culture and identification of Bacillus anthracis 
at the national and regional veterinary and public health laboratories.  
Therefore, the main objectives of this review are: to review laboratory diagnostic testing methods for 
anthrax and to understand reported outbreaks of anthrax in Ethiopia. 
2. BIOLOGY OF BACILLUS ANTHRACIS 
 Anthrax is disease caused by the spore forming bacteria B. anthracis. It is a Gram-positive, endospore 
forming, rod-shaped (Figure 1), non-motile bacterium that grows on nutrient media, typically sheep or horse 
blood, under aerobic or anaerobic conditions with an optimal temperature of 35-37oC [1, 2]. Colonies show as 
irregular, raised, opaque white to grey when grown on blood agar. The colonies are about 2mm in diameter 
and tacky on teasing with a loop [12]. Colonies cultured on media containing bicarbonate and incubated in 
high carbon dioxide (5-20%) will produce capsule, causing a mucoid phenotype [12]. Under a microscope, the 
vegetative form of the bacteria appears as square-ended in chains of two or more with an elliptical spore in the 
middle of the cell [1]. 
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Figure 1. Gram staining shows Gram-positive rods in long chains, photo taken in May 2, 2019 during anthrax  
outbreak investigation at the National Animal Health Diagnosis and Investigation Center, Ethiopia. 
 
Vegetative B. anthracis are poor to survive outside of a host and therefore produce endospores to 
survive long term in the environment [1, 13]. This characterizes B. anthracis as an obligate pathogen [12, 14, 
15]. An endospore is the inactive form of a vegetative cell and formed in the presence of oxygen, towards the 
ends of exponential growth [16]. For B. anthracis, the spore is considered the infectious particle [17].  
3. EPIDEMIOLOGY 
3.1. Occurrences 
 Anthrax occurs on all the continents and commonly causes high mortality, primary herbivorous 
animals [12]. In domestic animals there is high fatality in cattle, sheep, goats, donkeys and pigs [15]. For wild 
animals, highest fatalities occur in zebra, antelope, bison, gazelles, impalas, elephants and hippopotami [2, 
15]. Anthrax is the most common in agriculture region of central and South America, sub-Saharan Africa 
including Ethiopia, Central and southwestern Asia and southern Eastern Europe [18, 19]. 
 Spores live on for decades in soil that rich in calcium, has a pH greater than 6.0, and when temperature 
is higher than 15.5oC [20]. Anthrax disease is considered as a seasonal disease, because anthrax outbreaks 
follow a prolonged hot and dry period that is followed by heavy rainfall. It is thought that heavy rainfall can 
carry spores during runoff in clumps of organic matter to concentrate in standing pools or puddles. It is also 
thought that standing water can move spores upwards into the vegetation as it dries, leaving them in a better 
position to be ingested by grazing animals [20]. Spores are very resistant to heat, desiccation, cold, pH, 
chemicals and irradiation allowing them to survive in the environment for decades [1, 2]. 
3.2. Public Health Importance 
 Anthrax affects primarily herbivores animals. Humans usually become infected when butchering and 
eating of contaminated carcasses and come into contact with infected animals or their products and it is 
primarily an occupational hazard for handlers of processed hides, goat hair, bone products wool, infected 
wildlife and abattoir workers by contact with infected meat when contracted [21]. 
 Anthrax spore most likely spread as an aerosol and can also be used as a bio-warfare or bio-terrorism 
agent, therefore; any new case can be assessed with this possibility in mind, particularly but not exclusively in 
cases of pulmonary anthrax [22]. 
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3.3. Economic significance 
 Anthrax has significant economic impact by decreasing the efficiency which input or resources are 
converted into output or a product that means they reduced productivity. In most developing countries 
vaccination of susceptible animal in enzootic areas has decrease the prevalence of the disease to negligible 
proportions on national bases, but heavily losses may still occur in individual herds. Loss occurs due to 
mortality but also from withholding of milk in infected dairy herds and for a period following vaccination it 
also causes a great problem of death of animals, reducing animal products and complete condemnations of 
carcasses and by product as well as shutting down of abattoirs [23]. 
4. TRANSMISSIONS 
4.1. Transmission in animals 
 The B. anthracis naturally remain viable in the soil, but its life cycle almost entirely takes place within 
the mammalian host [1]. Under the right conditions, spores can live on for years in the environment. Animal 
hosts get the disease through grazing, usually by ingestion or inhalation [1, 18]. Once enters in to the host, the 
spores germinate into the active form of the bacterium and begin to multiply rapidly inside the animal. The 
bacilli are then able to spread through the host system using toxin and capsule production as outlined above. 
Once the infection becomes systemic, the host dies from shock and hemorrhages blood and other bodily 
liquids. After death, the vegetative cells are exposed to air causing sporulation to occur and the spores return 
to the soil for the next host [1, 12, 13, 15, 18].  
 Animal meat, hides, hair, wool or bones may be transported long distance and spores can be carried 
with wind currents to new areas, especially during dry period. Insects are also thought to play a role in disease 
transmission, primary through blow flies. Animals that have died or are dying from anthrax provide the main 
source of infection for other animals through shedding of bacilli, which eventually become spores, into the 
environment [15].  
4.2. Transmission in humans 
 In humans, anthrax transmitted in three major routes (ingestion, inhalation and cutaneous). The most 
common form of disease is cutaneous which accounts for 95% of human cases [18, 24]. This form is acquired 
through abrasions or open wounds on the skin that come into contact with either vegetative cells or spores. 
Cutaneous anthrax has a mortality rate of 5-20% for untreated cases [18]. Ingestion of anthrax develops after 
ingestion of spores or cells through contaminated meat. While uncommon, the mortality rate is thought to be 
much higher than cutaneous at 25-60%. The most fatal type of infection with anthrax is through inhalation 
which occurs from breathing in spores from environment [18].  
 Injection anthrax is becoming more common among intravenous (IV) drug user, which is characterized 
by cutaneous infection of soft tissue [25, 26]. This route presents differently than cutaneous infections, and 
has shown to be harder to treat, with infection leading to septic shock, meningitis and death in 34% patients 
despite treatment [18]. Biting insects are also thought to transmit disease, most prominently biting flies [2, 
20]. Anthrax is not considered contagious, although in rare instances, human-to-human transmission can occur 
in the cutaneous form [19]. 
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5. CLINICAL PROGRESSIONS 
5.1. Clinical progression in animals 
 In animals, the incubation period can range from as little as 36-72 hours following the entry of bacteria 
or spore to 1-14 days [15]. The common incubation period in livestock is 3-7 days. According to the OIE 
international trade regulation the incubation period is considered to be 20 days. Clinical manifestations differ 
from species to species, presumably reflecting differences in susceptibility. Sudden death, bloody discharges 
from natural orifices (rectum, mouth, nostrils, etc.) rapid bloating of the carcass, absence or incomplete rigor 
mortis and the absence of clotting of the blood are the common characteristics of anthrax in susceptible 
animals. In more resistant species, local signs such as swellings of the oral and pharyngeal region are seen. In 
wildlife, sudden death is the invariable sign, often (but not always) oozing of blood from natural orifices, 
bloating, incomplete rigor mortis, dark blood and fail to clot [15]. 
 Horses have hyperacute to acute disease with signs for 2-3 days before death. Frequently shows fever, 
severe colic, tremors, anorexia, depression, weakness, bloody diarrhea, and subcutaneous edema may be 
present on the neck, sternum, lower abdomen, and external genitalia. Death usually occurs within 2-3 days of 
onset. Sometimes, sick horses may live up to a week. Pigs are relatively resistant and infection is often 
subclinical. Clinical symptoms show localized swelling of pharynx, face and neck extending to chest and 
carnivores are more resistant and s typically have severe inflammatory edema of oropharynx and head, and 
acute gastroenteritis if clinically affected. Scavengers are relatively resistant [15].  
5.2. Clinical progression in humans 
 Cutaneous anthrax presents in as little as 12 hours to as long as 19 days after initial infection [12], but 
is typically 1-12 days [18, 27]. A small, painless skin lesion with swelling usually appears on exposed regions 
of the body such as the face, neck, arms or hands [12, 18, 19]. The lesion eventually dries and forms a black 
center, called an eschar which sloughs in 2-3 weeks [12, 18]. During this period, fever can occur but is rare. It 
should be noted that toxin can be detected in the bloodstream even when systemic disease is not present [28]. 
 Gastrointestinal of anthrax has an incubation period of about 2-5 days and can present in two different 
ways: Intestinal and oropharyngeal [12, 18]. During anthrax, vegetative cells cause ulcers or lesions 
throughout the small intestine [18]. Symptoms include nausea, vomiting, anorexia and fever [19]. In severe 
cases, abdominal pain, hematemesis, bloody diarrhea and septicemia can present. Oropharyngeal anthrax 
occurs when vegetative cells settle in the pharyngeal area and produce ulcers. Patients usually present with 
fever, neck swelling and sore throat [12, 19].  
 Inhalation of anthrax (also known as pulmonary) has the highest mortality and has historically been 
linked to industrial cases of disease, although bioterrorism has become the greatest concern in large-scale 
outbreaks [18, 24]. Inhalation cases take a biphasic clinical course and patients develop flu-like symptoms 
with fever, cough and myalgias after approximately four days [18].  
6. PATHOGENESIS 
 The major virulence factors of B. anthracis are encoded on two virulence plasmids. The plasmids are 
circular, extrachromosomal, double-stranded DNA molecule [29]. Infection occurs after contact of spore 
through a break in the skin (cutaneous anthrax) or entry through mucosa (gastrointestinal anthrax). After 
ingestion by macrophages at the site of entry, within hours after uptake spores germinate and vegetative 
encapsulated bacilli proliferate, together with the production of capsule and toxins. The capsule plays an 
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important role in establishment of the infection while the toxins are more prominent in the final stages of 
infection [13]. 
6.1. Toxins  
 Genes encoding toxins (pX01) includes genes for both lethal toxin and edema toxin while pX02 
includes genes for production and assembly of the capsule [1, 12, 13, 18]. The toxin complex is composed of 
three proteins: lethal factor (LF), edema factor (EF) and protective antigen (PA). PA is an intra member 
transporter that mediates cell binding and uptake of LF and EF [18]. Protective antigen (PA) in combination 
with EF and LF forms edema toxin and lethal toxin, respectively [1].  
 Edema toxin alters the production of cyclic-AMP (Adenosine monophosphate) which creates altered 
ions and water movements. This leads to the characteristic edema of anthrax. It is also thought to impair 
neutrophil function and prevent the inflammatory process [2]. Lethal toxin is an endopeptidese that disrupts 
signaling pathways and leads to the synthesis of cytokines that ultimately cause septic shock. It is also thought 
that lethal toxin may attack the endothelial cell linings of the capillary network that results in the necrosis of 
blood vessels. This leads to the characteristic hemorrhage from the nose, mouth and anus of infected hosts and 
the systematic release of bacilli into the environment, competing its life cycle [2].  
6.2. Capsule 
 The capsule is a polymer that encases the bacterium. The capsule of B. anthracis is unique in that it is 
made from the protein, poly-glutamic acid, and not carbohydrate. It is formed under elevated CO2 condition 
and in the presence of bicarbonate. The capsule allows virulent bacilli to grow unimpeded in the host for the 
initial stages of infection. It is theorized that the negative charge of the capsule inhibits host defense 
mechanisms, namely phagocytosis, allowing the bacteria to establish infection [30-32]. The plasmid pXO2 
(95.3 kbp) is the smaller capsule that encodes three genes (cap B, cap C, and cap A) and involved in the 
synthesis of the poly-glutamyl capsule that inhibits host phagocytosis of the vegetative form of B. anthracis 
[31].  
6.3. Spore and vegetative cell survival 
 Vegetative cells in unopened carcasses may survive for up to 1 to 2 weeks, but spores can persist for 
decades in a stable, dry environment. Spores are killed by autoclaving (121oC/15 min) and dry heat (150oC/60 
min), but not by boiling (100oC) for under 10 minutes. They are not highly susceptible to phenolic, alcoholic, 
oxidizing and chlorinating disinfectants, beta-propiolactone, and ethylene oxide are more useful. Heat fixation 
of smears does not kill spores [33]. 
7. DIAGNOSTICS 
 As various outbreaks are reported time to time from different areas, there is a great need of early 
diagnosis of the disease to save human and animal life. Besides, requirement of rapid and reliable detection, 
identification and diagnosis systems for anthrax has been emphasized by recent bioterrorism events. The early 
monitoring of the disease requires the detection of anthrax spores and infection both at environmental and 
clinical levels [34]. 
7.1. Culture and Gram staining 
 Bacterial culture and isolation are considered the gold standard and most important diagnostic tool for 
identification of B. anthracis and easy to grow on nutrient agar medium [35]. Specimen or culture can be 
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grown overnight on Sheep Blood agar at 35-37oC. However, on sheep Blood agar (5%) and other routine 
culture media, almost all Bacillus species grow well [36]. After incubation for 18-24 hours, growth occurs on 
blood agar and shows the characteristic morphology of grey/white, flat colonies, 2-5 mm in diameter, flat or 
slightly raised, gray to white with a "ground glass" appearance and described as "tenacious" or "sticky" like 
petroleum jelly. After 18 hours of incubation on sheep blood agar (SBA) at 35°C, the slightly undulate margin 
may show curling, displaying a so-called "Medusa head" or described as comma-shaped protrusions [19]. 
Colonies should be observed for hemolysis (the rupture of red blood cells resulting in clearing of the medium) 
after incubation and a Gram stain should also be performed. B. anthracis will be negative for hemolysis and 
appear as purple rods after Gram stain [37]. 
 
 
Figure 2. Colony morphology of B. anthracis on Sheep Blood agar, photo taken in June 1, 2019 during anthrax  
outbreak investigation at the National Animal Health Diagnosis and Investigation Center, Ethiopia. 
 
A selective media containing polymyxin-B, lysozyme, EDTA and thallous acetate (PLET media) can 
also be used for isolation of B. anthracis from contaminated and suspected samples [38]. It consists of heart 
infusion agar with polymyxin, lysozyme, ethylene diamine tetraacetic acid (EDTA) and thallous acetate (pH 
7.35). Commercial readymade PLET agar base is also available to be used with Anthracis Selective 
Supplement (FD185) [39]. Another media (bicarbonate agar) is used to induce capsule formation for 
subsequent identification of B. anthracis. However, there is very little utility of these selective growth media 
because several closely related bacteria of B. anthracis like B. cereus and B. subtilis also grow well on these 
media. 
7.2. Biochemical tests 
 Bacillus anthracis is highly susceptible to penicillin and B. cereus and the other spp are resistant.          
B. anthracis slowly produces an inverted fir tree type of gelatin liquefaction with side-shoots radiating from 
the stab line but  B. cereus, B. mycoides, B. thuringiensis rapidly liquefy nutrient gelatin and non-motile 
(Table 1). B. anthracis characterized by various biochemical tests like catalase, oxidase, nitrate reduction, 
haemolysis, citrate utilization, urease [40]. 
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Table 1. Differential characteristics of B. anthracis and B. cereus. 
 B. anthracis B. cereus 
Hemolysis - + 
Motility - + 
Lysis by gamma phage + - 
Capsule production + - 
Penicillin susceptibility (10 unit disc) S R 
+: positive reaction; -: negative reaction; S - Susceptible; R - Resistant; Quinn et al. [7]. 
 
7.3. Capsule production 
 Samples can also be tested for capsule production by incubation on certain types of agar followed by 
staining. Single colonies from Sheep Blood agar can be inoculated on to three different types of media. The 
first is Heart infusion broth (HIB) with 0.8% sodium bicarbonate. The broth should be incubated at 35-37oc 
for 6-8 hours. Incubation can happen at an ambient atmosphere in a Co2 enriched environment. The 
characteristic mucoid or smooth colony variant is correlated with capsule production ability of B. anthracis on 
capsule agar incubated in an atmosphere of 5% CO2. The second medium is defibrinated horse blood. This 
should be incubated at 35-37oC for 6-8 hours in an ambient atmosphere. The third medium is HIB 
supplemented with heat-inactivated horse serum and 0.8% sodium bicarbonate. This broth should be 
incubated at 35-37oC for 6-8 hours in an ambient atmosphere or in a CO2-enriched environment [15]. 
 M’Fadyean (Polychrome methylene blue) stain is a simple stain containing methylene blue that is 
applied to fixed smears to visualize capsule. After staining, bacilli will appear dark blue with a narrow area 
around and between that is red/purple. A sample of culture should be smeared on a microscope slide and 
allowed to dry and then be heat-fixed. Stain is added to the smear and rinsed. The slide can be viewed at 40x 
or 100x with oil immersion [41]. M’Fadyean-stained blood smears examined at death will reveal large 
numbers of the capsulated bacilli which can also be isolated and confirmed bacteriologically [15]. 
7.4. Gamma-phage lysis 
 Gamma-phage is a bacterial virus that specifically lyses B. anthracis with 96% specificity. Most other 
strains of the B. cereus groups are not susceptible to lysis by Gamma-phage. A single colony is spread onto 
Sheep Blood agar plate, and small amount of gamma phage is aliquoted onto the first or second quadrant. If 
the test organism is susceptible to the phage, a clear zone of lysis will be present after overnight incubation at 
35-37oC. While gamma-phage lysis is a simple test to perform, proper propagation of active gamma-phage is 
essential. Unstable phage preparation can lead to false-negative results [15]. 
7.5. Serological tests 
7.5.1. Enzyme-Linked Immunosorbent Assay (ELISA) 
 For serodiagnosis of cutaneous anthrax, an enzyme-linked immunosorbent assay was developed in 
India for determination of anti-PA IgGs with 99.4% specificity and 100% sensitivity [42]. A field-based 
qualitative visual ELISA for anti-PA IgG was also developed for serodiagnosis of anthrax [43]. Results of 
sensitivity and specificity of visual ELISA were found compatible with the results obtained from standard 
ELISA measuring OD values. Likewise, a quantitative ELISA was developed for measurement of the anti-PA 
IgG level in human serum samples [44]. The minimum detection limits and lower limits of quantification of 
Olani et al.   Laboratory diagnostic methods and reported outbreaks of anthrax in Ethiopia 89 
European Journal of Biological Research 2020; 10(2): 81-95 
the assay for anti-PA IgG were 3.2 μg/mL and 4 μg/mL, respectively. The serum samples collected from the 
anthrax infected patients were found to have anti-PA IgG concentrations of 5.2 to 166 μg/mL [44]. 
7.5.2. Ascoli test 
 This test is to supply rapid retrospective evidence of anthrax infection in an animal. It was designed to 
detect B. anthracis antigens in the tissues of animals being utilized in animal by-products, and thereby to 
reveal when these products contained ingredients originating from animals that had died of anthrax [15]. This 
thermo-precipitation test is used if viable B. anthracis can no longer be demonstrated in tissues. About 2-3 g 
of homogenized materials in a little saline is briefly boiled and passed through filter paper. This filtrate is used 
as the antigen in a ring precipitation or gel diffusion test with known B. anthracis precipitating antiserum and 
the test is not suitable for detection of B. anthracis in environmental specimens [7]. 
7.6. MALDI-TOF mass spectrometry 
 Matrix Assisted Laser desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS) can 
be utilized to detect lethal factor in serum samples of patients in the acute stage of illness. MALDI-TOF MS is 
a molecular technique used to separate protein or peptides of samples, seen as peaks on a spectrum. By 
analyzing serum samples mixed with a peptide that can be cleaved by lethal factor (LF), the presence of LF in 
the sample can be determined. If it is not present, a single protein peak will be seen after MALDI-TOF MS 
analysis while if LF is present, two distinct peaks will be seen as a result of the cleavage. This is only 
applicable to acute samples, as LF is circulating in the blood at that time [45]. 
7.7. Molecular diagnostics 
 Over recent years there have been several reports describing the use of molecular techniques for 
genotyping and distinguishing/ identification B. anthracis [46, 47], such as Multi Locus Sequence Typing 
(MLST) [48, 49], Multi Locus VNTR Analysis (MLVA) [50, 51], Single Nucleotide Repeat (SNR) Analysis 
[52], and real-time PCR Assays [49, 53-58]. The main targets to demonstrate virulence are the plasmids pXO1 
and pXO2, encoding the toxin and capsule genes, respectively. Isolates lacking either one or both plasmids 
(pXO1_/ pXO2_) have been described. Only in conjunction with specific chromosomal markers insight into 
the backbone or genetic background can be gained to understand the pathogenic nature of B. anthracis. Due to 
lack of a specific chromosomal marker, differentiation of the pXO1_/pXO2_ form of B. anthracis from 
closely related B. cereus group species is difficult. In addition, naturally occurring as well as genetically 
modified B. anthracis strains cannot be characterized without ambiguity and differentiation of these strains 
from those B. cereus isolates that carry plasmids harbouring portions of B. anthracis-specific plasmids is a 
challenge [59, 60]. 
7.8. Differential diagnosis 
 Anthrax should be differentiated from other causes of sudden death such as: lightning strike and 
accidental electrocutions, pasteurellosis, piroplasmosis, blackleg, malignant oedema, food intoxications, 
botulism, peracute babesiosis, chemical poisoning (heavy metal and other poisoning), plant poisoning, snake 
bite, metabolic disorders (lactic acidosis), magnesium deficiency, bloat and others [61]. 
8. REPORTED OUTBREAKS OF ANTHRAX IN ETHIOPIA 
 Anthrax is an endemic disease which occurs in May and June every year (‘anthrax season’) in several 
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farming localities of the country, causing disease both in domestic and wild animals and humans. It is still a 
significant risk in most regions in Ethiopia and outbreaks frequently occur in humans and animals. In the 
country a retrospective record review from 2009-2013 showed that within five years a total of 26737 animal 
cases with 8523 animal deaths due to anthrax were reported [62]. This data showed that each year on average 
death of 1705 animals were recorded due to anthrax. Based on the report of Shiferaw [11] 26 cases of anthrax 
in animals were reported in Wabessa village of Dessie Zuria district, as a result death of 26 animals were 
recorded from the outbreak.  
 Moreover, retrospective study on the epidemiology of bovine anthrax in Elu Aba Bor Zone, South West 
Ethiopia showed that from the period of 2009-2016 within 8 years duration a total of 405 anthrax outbreaks 
with 1166 case and 739 deaths in cattle were registered (Table 2). This data revealed that each year 50 
outbreaks of anthrax occurred in the area. Based on the report the hot dry season accounted for 29.6% of the 
outbreaks followed by the rainy and cold dry season (24.69%), and the post rainy season recorded the lowest 
proportion 20.99% [63].  
 
Table 2. Animal and human anthrax cases and deaths reported in different parts of Ethiopia. 
Year 
Animal Human 
References 
Cases Death Cases Death 
2018 NR* NR* 38 1 [60] 
2009-2016 1166 739 NR* NR* [56] 
2010–2013 NR* NR* 8 1 [59] 
2009-2013 26737 8523 5197 86 [55] 
2011-2012 NR* NR* 3 0 [58] 
2002 26 26 6 3 [12] 
Total 27,929 9,288 5,250 91  
Note: NR* means not reported 
 
 In wildlife anthrax outbreak has been reported in southern parts of Mago national parks and spread to 
the northern part within two months beginning from September 1999. Moreover, another anthrax outbreak 
from September to October 2000 has also been reported in this park. According to the report in the first 
outbreak more than 1,600 wild animals were dead from 21 different species. Of all the species Lesser kudu 
was severely affected, which accounts for 95% of mortality and as a result more than 65% of Lesser Kudu’s 
population within the park died [64].  
 Bahiru et al. [62] retrospective data showed that, a total of 5,197 human anthrax cases were reported 
from 2009 to 2013 with 86 human anthrax deaths (Case Fatality Rate: 1.7%) nationally. Human prevalence 
was found to be 1.3 per 100,000 populations per five years and this report revealed that each year on average 
17 people death was recorded due to anthrax in the country. Based on the Shiferaw [11] report, 6 human cases 
and 3 human deaths were recorded due to anthrax in Dessie Zuria district of Amhara Regional state. As 
reported by Shiferaw et al. [65], a case series of 3 patients with periocular anthrax that were seen at Jimma 
University Specialized Hospital, Ethiopia from June 2011 to May 2012 and all the three patients were 
responded to intravenous antibiotics and the lesion resolved leaving scars which caused cicatricial ectropion. 
 Cutaneous anthrax cases were admitted to the rural General Hospital of Gambo, West Arsi Province of 
Ethiopia from 2010-2013 in eight patients (six female and two male, age range 1-56 years) as reported by 
Pérez-Tanoira et al. [66].  According to Pérez-Tanoira et al. [66] report, one patient suffered the loss of an 
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eyeball, and another died 12 hours after starting treatment. However, patients responded to treatment, and the 
lesions resolved, leaving eschars. Physicians working in rural areas of resource-poor settings should be trained 
in the clinical identification of cutaneous anthrax and early antibiotic treatment is recommended for 
decreasing morbidity and mortality. Moreover, Ethiopian weekly Epidemiological Bulletin of Ethiopian 
Public Health Institute reported 38 human cases and 1 death due to anthrax from different part of the country 
within one week in May 2018 [67]. 
9. TREATMENT AND PREVENTIONS 
 The control of anthrax outbreaks among domestic animals is primarily dependent on rapid 
identification and treatment of affected animals; enhanced surveillance for additional cases; implementation 
of control measures including quarantine, prophylaxis, and vaccination; prevention of animal access to 
suspected sources such as potentially contaminated feed or pastures; and appropriate disposal of infected 
carcasses and disinfection of affected premises. 
 The recommended procedure for treating animals showing clinical illness in which anthrax is thought 
to be the likely or possible cause is immediate intravenous administration of sodium benzylpenicillin as 
directed by the manufacturer’s instructions (usually in the range 12 000–22 000 units per kg of body weight) 
followed 6-8 hours later by intramuscular injection of long-acting benzathine penicillin (manufacturers’ 
instructions usually recommend a dose within the range of 6000–12 000 units per kg of body weight) or other 
appropriate preparation such as Clamoxyl® (15 mg/kg), a long-acting preparation of amoxicillin [15]. 
 If long-acting preparations are unavailable, procaine penicillin (the dose recommended by 
manufacturers is usually 6000–12 000 units/kg) can be used for intramuscular injection, but should be 
administered again after 24 and 48 hours. Recommended doses of streptomycin to be administered together 
with penicillin intramuscularly are 5-10 mg per kg body weight in large animals and 25-100 mg per kg body 
weight in small animals [15]. 
 Bacillus anthracis is susceptible to numerous antibiotics but treatment must begin early enough in 
infection to be successful. Penicillin and ciprofloxacin are considered the drug of choice although tetracycline, 
chloramphenicol, aminoglycosides, macrolides, imipenem, rifampicin and vancomycin can be used 
commonly in human [12, 13, 19]. Antibiotic treatment usually continues for 7-10 days although it can be 
extended in severe cases [12]. Along with antibiotics treatment, supportive care may be required as fluid 
drainage, blood pressure support and mechanical assistance with breathing [15]. 
 Vaccination of host animals particularly cattle, sheep and horses, remains the gold standard for 
prevention of anthrax among both animals and people [2]. The veterinary anthrax vaccine is a live strain that 
contains the pXO1 plasmid but is missing the pXO2, meaning it is toxinogenic but non-encapsulated [1].  
10. CONCLUSION AND RECOMMENDATIONS 
 Anthrax is an infectious disease caused by the bacteria B. anthracis and it affects both animals and 
humans. Generally, the disease causes a great problem by death of animals, prevent utilization of animal 
products and complete condemnation of carcasses and by-products as well as closure of abattoirs. The 
causative organism is sensitive to many antimicrobial agents. This review indicated that anthrax remains to be 
a major public and veterinary health problem in Ethiopia. Prevention and control of anthrax in animals 
effectively reduces its impact on public health and the national economy. A multi-sectoral collaborative 
approach and capacity building are essential for successful prevention and control of anthrax.  
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 As the disease is endemic in Ethiopia and mostly under-reported, the following recommendations are 
forwarded:  
• Strengthening diagnostic capacity of both veterinary and public health laboratories is very important for 
timely diagnosis, treatment, prevention, control and reporting of the disease. 
• The regional laboratories should have been trained on biosafety, sample collection and diagnosis of anthrax 
suspected cases and investigation of any sudden or unexpected death in livestock. 
• Active surveillance, proper animal immunization and awareness creation is important to curb the disease. 
• Reported anthrax cases should be classified as suspected, probable and confirmed as per the WHO 
recommended case definition. 
• Proper decontamination of the site where the dead animal was founds. 
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